Dayron Ortega
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1437684693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $910 and has fallen 96.5% since, to $32 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 61 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$247
- Dexcom, Inc.$216
- Corcept Therapeutics$192
- Xeris Pharmaceuticals, Inc.$164
- Amgen$136
- Insulet Corporation$63
- plus $402 from 14 others
What the payments were for
- Food & beverage$1,37597%
- Education$453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $247 |
| Dexcom, Inc. | 6 | $216 |
| Corcept Therapeutics | 4 | $192 |
| Xeris Pharmaceuticals, Inc. | 9 | $164 |
| Amgen(2 entities) | 8 | $136 |
| Insulet Corporation | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Bayer | 3 | $53 |
| Novo Nordisk | 2 | $45 |
| Recordati_rare_diseases_inc. | 2 | $43 |
| Merck | 2 | $41 |
| Novartis | 1 | $24 |
| Medtronic | 1 | $23 |
| Mannkind Corporation | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Boehringer Ingelheim | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$146
- DEXCOM G7 GSS (161)$125
- RETEVMO$111
How this compares
$1,420 in reported general payments places this provider in the 35th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Other endocrinology, diabetes & metabolism in Miami
- Jay SkylerMiami$2.2M
- Eugenio Angueira-SerranoMiami$603K
- Rodolfo GalindoMiami$229K
- Camillo RicordiMiami$128K
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.